Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ME 23andMe	$0.50 -35.3%	$0.50	$0.53 ▼ $9.57	$13.36M	1.19	1.57 million shs	29.28 million shs
TELO Telomir Pharmaceuticals	$1.55 -2.2%	$1.71	$1.12 ▼ $8.40	$46.13M	-0.67	1.40 million shs	57,811 shs
UNCY Unicycive Therapeutics	$4.04 +0.6%	$5.47	$2.02 ▼ $11.00	$51.00M	1.88	355,427 shs	132,322 shs
VRCA Verrica Pharmaceuticals	$6.86 +2.3%	$6.62	$3.82 ▼ $58.20	$63.41M	1.92	41,895 shs	45,749 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ME 23andMe	0.00%	0.00%	0.00%	0.00%	-93.11%
TELO Telomir Pharmaceuticals	+1.28%	-13.66%	+36.21%	-42.55%	-63.17%
UNCY Unicycive Therapeutics	-1.96%	-4.30%	-19.96%	-33.80%	+12.96%
VRCA Verrica Pharmaceuticals	+5.51%	+20.29%	-16.94%	+21.82%	-86.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ME 23andMe	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	3.2301 of 5 stars	3.8	4.0	0.0	0.0	2.2	0.0	0.6
UNCY Unicycive Therapeutics	2.4231 of 5 stars	3.7	2.0	0.0	0.0	1.9	1.7	0.6
VRCA Verrica Pharmaceuticals	4.1121 of 5 stars	3.1	2.0	0.0	4.7	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ME 23andMe	0.00	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	849.37% Upside
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,396.26% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$80.00	1,094.03% Upside

Current Analyst Ratings Breakdown

Latest ME, UNCY, TELO, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ME 23andMe	$208.78M	0.06	$0.54 per share	0.93	$2.34 per share	0.21
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A
UNCY Unicycive Therapeutics	$680K	74.54	N/A	N/A	$0.72 per share	5.57
VRCA Verrica Pharmaceuticals	$7.57M	8.19	N/A	N/A	($1.07) per share	-6.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ME 23andMe	-$666.70M	-$15.45	N/A	∞	N/A	-183.39%	-170.07%	-62.13%	N/A
TELO Telomir Pharmaceuticals	-$16.53M	-$0.42	N/A	N/A	N/A	N/A	-2,009.40%	-1,009.72%	8/12/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	8/13/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$12.00	N/A	N/A	N/A	N/A	N/A	-145.63%	8/12/2025 (Estimated)

Latest ME, UNCY, TELO, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	UNCY Unicycive Therapeutics	-$0.70	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	TELO Telomir Pharmaceuticals	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.10	N/A	N/A	N/A	$4.37 million	N/A
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$1.40	-$0.50	+$0.90	-$0.05	N/A	N/A
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$1.40	-$1.00	+$0.40	-$0.10	$2.53 million	$3.44 million
5/12/2025	Q1 2025	TELO Telomir Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ME 23andMe	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ME 23andMe	N/A	1.05	0.91
TELO Telomir Pharmaceuticals	N/A	0.75	0.75
UNCY Unicycive Therapeutics	N/A	1.64	1.64
VRCA Verrica Pharmaceuticals	N/A	1.34	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ME 23andMe	36.10%
TELO Telomir Pharmaceuticals	N/A
UNCY Unicycive Therapeutics	40.42%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ME 23andMe	26.32%
TELO Telomir Pharmaceuticals	N/A
UNCY Unicycive Therapeutics	10.71%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	9.25 million	4.26 million	Optionable

ME, UNCY, TELO, and VRCA Headlines

Recent News About These Companies

3VRCA : What to Expect from Verrica Pharmaceuticals's Earnings

August 11 at 8:05 PM | benzinga.com

Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday

August 10 at 3:37 AM | americanbankingnews.com

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from Brokerages

August 5, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?

August 3, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%

August 2, 2025 | marketbeat.com

Verrica Pharmaceuticals Implements Reverse Stock Split

August 1, 2025 | theglobeandmail.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Gap Down - What's Next?

July 26, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed ...

July 11, 2025 | seekingalpha.com

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

July 9, 2025 | globenewswire.com

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 1, 2025 | globenewswire.com

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

June 27, 2025 | news.bloomberglaw.comN

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ME, UNCY, TELO, and VRCA Company Descriptions

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Telomir Pharmaceuticals NASDAQ:TELO

$1.54 -0.04 (-2.22%)

As of 11:50 AM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Unicycive Therapeutics NASDAQ:UNCY

$4.04 +0.03 (+0.62%)

As of 11:49 AM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Verrica Pharmaceuticals NASDAQ:VRCA

$6.86 +0.16 (+2.31%)

As of 11:43 AM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time